Several families of transcription factors were identified as the master regulators in the pathogenesis of inflammatory diseases. These regulations including inflammation and immune responses, proliferation, apoptosis, and expression of specific vital genes. For instance, NF-kB, one of the master regulators, regulates many pro-inflammatory genes involved in the disease progression. Therefore, it could be a viable option to develop small inhibitors aimed for the specific inhibition of these pro-inflammatory proteins to treat various inflammation-based diseases. Further improvements are needed to avoid the risk of undesired side effects during the regimen, which can be achieved by identifying the natural products based on small molecules.
In this context, a complete understanding of these various inflammatory signaling events will pave the way to find specific novel molecules that interfere with the inflammatory signaling pathways and ultimately contribute to improving therapeutic strategies. Therefore, it is imperative to provide an update and find a novel plant-based and small synthetic molecule for the therapy of inflammatory-mediated diseases. Therefore, under this research topic, we are interested in receiving full-length research and review articles in small molecule inhibitors for inflammatory signaling pathways, in the context of novel therapeutics associated with inflammatory mediated diseases such as diabetes, cancer and cardiovascular diseases.
The proposed topics of interest include, but not limited to:
1. Molecular and cellular basis of the NF-kB activation and contribution of inflammation and immune dysregulation in the initiation and progression of various inflammatory diseases including rheumatoid arthritis, atherosclerosis, diabetes, multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuritis, asthma and inflammatory bowel disease.
2. Inflammatory response in relation to COVID-19 and other prothrombotic phenotypes, Helicobacter pylori-associated gastritis and systemic inflammatory response syndrome.
3. Genetic and genomic approaches and other omics tools to study inflammatory diseases. Inflammatory signaling mediated metabolic dysregulation, immune association, and therapeutic strategies with pharmacological modulation.
4. Molecular and cellular mechanisms of the novel small molecules and their role in treating inflammatory mediated diseases.
5. Development of pharmacologically important novel plant-based small molecules for targeting immune associated diseases; elucidating modulatory mechanisms.
6. Translational and clinical implications of small molecules for controlling inflammation mediated diseases.
Several families of transcription factors were identified as the master regulators in the pathogenesis of inflammatory diseases. These regulations including inflammation and immune responses, proliferation, apoptosis, and expression of specific vital genes. For instance, NF-kB, one of the master regulators, regulates many pro-inflammatory genes involved in the disease progression. Therefore, it could be a viable option to develop small inhibitors aimed for the specific inhibition of these pro-inflammatory proteins to treat various inflammation-based diseases. Further improvements are needed to avoid the risk of undesired side effects during the regimen, which can be achieved by identifying the natural products based on small molecules.
In this context, a complete understanding of these various inflammatory signaling events will pave the way to find specific novel molecules that interfere with the inflammatory signaling pathways and ultimately contribute to improving therapeutic strategies. Therefore, it is imperative to provide an update and find a novel plant-based and small synthetic molecule for the therapy of inflammatory-mediated diseases. Therefore, under this research topic, we are interested in receiving full-length research and review articles in small molecule inhibitors for inflammatory signaling pathways, in the context of novel therapeutics associated with inflammatory mediated diseases such as diabetes, cancer and cardiovascular diseases.
The proposed topics of interest include, but not limited to:
1. Molecular and cellular basis of the NF-kB activation and contribution of inflammation and immune dysregulation in the initiation and progression of various inflammatory diseases including rheumatoid arthritis, atherosclerosis, diabetes, multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuritis, asthma and inflammatory bowel disease.
2. Inflammatory response in relation to COVID-19 and other prothrombotic phenotypes, Helicobacter pylori-associated gastritis and systemic inflammatory response syndrome.
3. Genetic and genomic approaches and other omics tools to study inflammatory diseases. Inflammatory signaling mediated metabolic dysregulation, immune association, and therapeutic strategies with pharmacological modulation.
4. Molecular and cellular mechanisms of the novel small molecules and their role in treating inflammatory mediated diseases.
5. Development of pharmacologically important novel plant-based small molecules for targeting immune associated diseases; elucidating modulatory mechanisms.
6. Translational and clinical implications of small molecules for controlling inflammation mediated diseases.